ストックスクリーナーアプリを入手
5.04
21.89%
0.905
前日終値:
$4.135
開ける：
$4.19
24時間の取引高:
2.29M
Relative Volume:
7.34
時価総額：
$163.68M
収益：
$124.00K
当期純損益:
$-49.99M
株価収益率:
-4.5405
EPS:
-1.11
ネットキャッシュフロー:
$-31.03M
1週間 パフォーマンス:
+32.63%
1か月 パフォーマンス:
-11.27%
6か月 パフォーマンス:
-52.36%
1年 パフォーマンス:
+460.00%
1日の値動き範囲:
$4.19
$5.57
1週間の範囲:
$3.83
$5.57
52週間の値動き範囲:
$0.77
$14.30
Candel Therapeutics Inc Stock (CADL) Company Profile
CADL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CADL | 5.04 | 163.68M | 124.00K | -49.99M | -31.03M | -1.11 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-08-23 | 開始されました | Credit Suisse | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
| 2021-08-23 | 開始されました | UBS | Buy |
Candel Therapeutics Inc (CADL) 最新ニュース
Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment - Proactive Investors USA
HC Wainwright Issues Pessimistic Estimate for CADL Earnings - MarketBeat
Analysts Issue Forecasts for CADL Q4 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - Defense World
What is HC Wainwright's Estimate for CADL Q4 Earnings? - MarketBeat
Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges - TipRanks
Candel Therapeutics' (CADL) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - MarketBeat
Candel Therapeutics Inc (CADL) Quarterly 10-Q Report - Quartzy
Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up - Proactive Investors USA
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics Reports $10.6M Q3 Loss, Advances Key Cancer Drug Trials for Q4 2024 | CADL Stock News - StockTitan
Insiders Could Have Profited By Holding onto Candel Therapeutics Shares Despite 10% Drop - Simply Wall St
Candel Therapeutics’ CAN-3110 offers new hope for melanoma treatment – ICYMI - Proactive Investors USA
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Candel Therapeutics CEO to present at Jefferies London healthcare conference - Proactive Investors UK
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 - GlobeNewswire
Candel Therapeutics (NASDAQ:CADL) Shares Up 2.5%Should You Buy? - MarketBeat
Candel Therapeutics presents preclinical data with CAN-3110 in Melanoma model at SITC annual Meeting - Proactive financial news
Candel Therapeutics to Present Preclinical Data at SITC - GlobeNewswire
Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results - Proactive Investors UK
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma - StockTitan
Nfi Group Inc. (NFI-T) QuotePress Release - The Globe and Mail
Candel Therapeutics: A Low-Price Oncolytic Virus Play Further Along Than You Think - Seeking Alpha
Candel Therapeutics Advances in Cancer Treatment Trials - Yahoo Finance
Candel Therapeutics Showcases Innovative Cancer Therapy - GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) - StockTitan
Candel Therapeutics Prices IPO At $8/Share - RTTNews
Where are the Opportunities in (CADL) - Stock Traders Daily
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End - Proactive Investors Australia
Candel Therapeutics Share PriceCADL, RNS News, Articles, Quotes, & Charts (NASDAQ:CADL) - Proactive Investors USA
(CADL) Trading Advice - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares - MarketBeat
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Banxa Holdings Inc (BNXAF) QuotePress Release - The Globe and Mail
How To Trade (CADL) - Stock Traders Daily
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - The Manila Times
Candel Therapeutics to Present Preclinical Data on - GlobeNewswire
Candel therapeutics insider sells shares worth over $240k By Investing.com - Investing.com South Africa
Candel therapeutics insider sells shares worth over $240k - Investing.com India
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares - MarketBeat
Citigroup Raises Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - Defense World
Citi raises Cogent price target on bezuclastinib potential - Investing.com India
Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex
(CADL) Proactive Strategies - Stock Traders Daily
Gaining Ground: Cogent Biosciences Inc (COGT) Closes Lower at 10.65, Down -3.01 - The Dwinnex
Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
Cintas Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
Farallon Capital Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Kayne Anderson Rudnick Investment Management LLC Trims Holdings in Copart, Inc. (NASDAQ:CPRT) - Defense World
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):